Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Dec;62(6):915–918. doi: 10.1038/bjc.1990.408

Distribution of pimonidazole and RSU 1069 in tumour and normal tissues.

L M Cobb 1, J Nolan 1, S A Butler 1
PMCID: PMC1971577  PMID: 2257219

Abstract

The tritium-labelled analogues of pimonidazole and RSU 1069 were injected into mice bearing the KHT murine sarcoma which has a hypoxic cell fraction of approximately 10%. The distribution of activity at 24 h was recorded using autoradiography and measurement of tissue activity. Autoradiographs with both drugs showed high activity in particular cells within tumour, eye (melanin-associated cells), eyelid (Meibomian gland), liver (centrilobular area), skin (sebaceous gland and melanin), stomach (squamous area), footpad, oesophagus, labial gland, Zymbal's gland, preputial gland, parotid gland (intralobular ducts) and airway epithelium. These tissues had previously been identified as sites of binding of misonidazole. The measurement of total tissue radioactivity showed significantly higher activity in liver, eyelid (Meibomian gland), oesophageal lining, kidney and labial gland than was found in the tumour.

Full text

PDF
916

Images in this article

916Figure 1
on p.916
917Figure 2
on p.917

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams G. E., Ahmed I., Sheldon P. W., Stratford I. J. Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo. Br J Cancer. 1984 May;49(5):571–577. doi: 10.1038/bjc.1984.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ahmed I., Jenkins T. C., Walling J. M., Stratford I. J., Sheldon P. W., Adams G. E., Fielden E. M. Analogues of RSU-1069: radiosensitization and toxicity in vitro and in vivo. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1079–1081. doi: 10.1016/0360-3016(86)90230-0. [DOI] [PubMed] [Google Scholar]
  3. Asquith J. C., Watts M. E., Patel K., Smithen C. E., Adams G. E. Electron affinic sensitization. V. Radiosensitization of hypoxic bacteria and mammalian cells in vitro by some nitroimidazoles and nitropyrazoles. Radiat Res. 1974 Oct;60(1):108–118. [PubMed] [Google Scholar]
  4. Chapman J. D., Franko A. J., Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer. 1981 Apr;43(4):546–550. doi: 10.1038/bjc.1981.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cobb L. M., Hacker T., Nolan J. NAD(P)H nitroblue tetrazolium reductase levels in apparently normoxic tissues: a histochemical study correlating enzyme activity with binding of radiolabelled misonidazole. Br J Cancer. 1990 Apr;61(4):524–529. doi: 10.1038/bjc.1990.118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cobb L. M., Nolan J. Autoradiographic study of tritium-labeled misonidazole in the mouse. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):953–956. doi: 10.1016/0360-3016(89)90894-8. [DOI] [PubMed] [Google Scholar]
  7. Cobb L. M., Nolan J., Butler S. Tissue distribution of 14C- and 3H-labelled misonidazole in the tumor-bearing mouse. Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):347–351. doi: 10.1016/0360-3016(90)90099-6. [DOI] [PubMed] [Google Scholar]
  8. Cobb L. M., Nolan J., O'Neill P. Microscopic distribution of misonidazole in mouse tissues. Br J Cancer. 1989 Jan;59(1):12–16. doi: 10.1038/bjc.1989.4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cobb L. M. Toxicity of the selective antitumor agent 5-aziridino-2,4-dinitrobenzamide in the rat. Toxicol Appl Pharmacol. 1970 Jul;17(1):231–238. doi: 10.1016/0041-008x(70)90147-x. [DOI] [PubMed] [Google Scholar]
  10. Dische S. Radiotherapy using the hypoxic cell sensitizer Ro 03-8799 in malignant melanoma. Radiother Oncol. 1987 Oct;10(2):111–116. doi: 10.1016/s0167-8140(87)80053-1. [DOI] [PubMed] [Google Scholar]
  11. Dische S., Saunders M. I., Bennett M. H., Dunphy E. P., Des Rochers C., Stratford M. R., Minchinton A. I., Wardman P. A comparison of the tumour concentrations obtainable with misonidazole and Ro 03-8799. Br J Radiol. 1986 Sep;59(705):911–917. doi: 10.1259/0007-1285-59-705-911. [DOI] [PubMed] [Google Scholar]
  12. Dische S., Saunders M. I., Dunphy E. P., Bennett M. H., Des Rochers C., Stratford M. R., Minchinton A. I., Orchard R. A. Concentrations achieved in human tumors after administration of misonidazole, SR-2508 and Ro 03-8799. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1109–1111. doi: 10.1016/0360-3016(86)90237-3. [DOI] [PubMed] [Google Scholar]
  13. Franko A. J., Raleigh J. A., Sutherland R. G., Soderlind K. J. Metabolic binding of misonidazole to mouse tissues. Comparison between labels on the ring and side chain, and the production of tritiated water. Biochem Pharmacol. 1989 Feb 15;38(4):665–670. doi: 10.1016/0006-2952(89)90213-x. [DOI] [PubMed] [Google Scholar]
  14. Garrecht B. M., Chapman J. D. The labelling of EMT-6 tumours in BALB/C mice with 14C-misonidazole. Br J Radiol. 1983 Oct;56(670):745–753. doi: 10.1259/0007-1285-56-670-745. [DOI] [PubMed] [Google Scholar]
  15. Horwich A., Holliday S. B., Deacon J. M., Peckham M. J. A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitiser RSU-1069. Br J Radiol. 1986 Dec;59(708):1238–1240. doi: 10.1259/0007-1285-59-708-1238. [DOI] [PubMed] [Google Scholar]
  16. Laurent F., Canal P., Soula G. Pharmacokinetics of Ro 03-8799 in mice bearing melanosarcoma: comparison with tumors without melanin. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):1101–1103. doi: 10.1016/0360-3016(89)90926-7. [DOI] [PubMed] [Google Scholar]
  17. Lespinasse F., Thomas C., Bonnay M., Malaise E. P., Guichard M. Ro 03-8799: preferential relative uptake in human tumor xenografts compared to a murine tumor: comparison with SR-2508. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):1105–1109. doi: 10.1016/0360-3016(89)90927-9. [DOI] [PubMed] [Google Scholar]
  18. Maxwell A. P., MacManus M. P., Gardiner T. A. Misonidazole binding in murine liver tissue: a marker for cellular hypoxia in vivo. Gastroenterology. 1989 Nov;97(5):1300–1303. doi: 10.1016/0016-5085(89)91703-4. [DOI] [PubMed] [Google Scholar]
  19. Maxwell R. J., Workman P., Griffiths J. R. Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):925–929. doi: 10.1016/0360-3016(89)90888-2. [DOI] [PubMed] [Google Scholar]
  20. Merz G. S., Schwenk V., Schuller-Levis G., Gruca S., Wisniewski H. M. Isolation and characterization of macrophages from scrapie-infected mouse brain. Acta Neuropathol. 1987;72(3):240–247. doi: 10.1007/BF00691096. [DOI] [PubMed] [Google Scholar]
  21. Pette D., Brandau H. Enzym-Histiogramme und Enzymaktivitätsmuster der Rattenleber. Nachweis Pyridinnukleotid-spezifischer Dehydrogenasen im Gelschicht-Verfahren. Enzymol Biol Clin (Basel) 1966;6(2):79–122. [PubMed] [Google Scholar]
  22. Raleigh J. A., Franko A. J., Treiber E. O., Lunt J. A., Allen P. S. Covalent binding of a fluorinated 2-nitroimidazole to EMT-6 tumors in Balb/C mice: detection by F-19 nuclear magnetic resonance at 2.35 T. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1243–1245. doi: 10.1016/0360-3016(86)90268-3. [DOI] [PubMed] [Google Scholar]
  23. Rasey J. S., Grunbaum Z., Magee S., Nelson N. J., Olive P. L., Durand R. E., Krohn K. A. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res. 1987 Aug;111(2):292–304. [PubMed] [Google Scholar]
  24. Rauth A. M. Pharmacology and toxicology of sensitizers: mechanism studies. Int J Radiat Oncol Biol Phys. 1984 Aug;10(8):1293–1300. doi: 10.1016/0360-3016(84)90335-3. [DOI] [PubMed] [Google Scholar]
  25. Roberts J. T., Bleehen N. M., Walton M. I., Workman P. A clinical phase I toxicity study of Ro 03-8799: plasma, urine, tumour and normal brain pharmacokinetics. Br J Radiol. 1986 Feb;59(698):107–116. doi: 10.1259/0007-1285-59-698-107. [DOI] [PubMed] [Google Scholar]
  26. Saunders M. I., Anderson P. J., Bennett M. H., Dische S., Minchinton A., Stratford M. R., Tothill M. The clinical testing of Ro 03-8799--pharmacokinetics, toxicology, tissue and tumor concentrations. Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1759–1763. doi: 10.1016/0360-3016(84)90544-3. [DOI] [PubMed] [Google Scholar]
  27. Stratford I. J., Adams G. E., Godden J., Howells N. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo. Int J Radiat Biol. 1989 Mar;55(3):411–422. doi: 10.1080/09553008914550451. [DOI] [PubMed] [Google Scholar]
  28. Stratford I. J., Walling J. M., Silver A. R. The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action. Br J Cancer. 1986 Mar;53(3):339–344. doi: 10.1038/bjc.1986.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Stratford I. J., Williamson C., Hoe S., Adams G. E. Radiosensitizing and cytotoxicity studies with CB 1954 (2,4-dinitro-5-aziridinylbenzamide). Radiat Res. 1981 Dec;88(3):502–509. [PubMed] [Google Scholar]
  30. Van Os-Corby D. J., Koch C. J., Chapman J. D. Is misonidazole binding to mouse tissues a measure of cellular pO2? Biochem Pharmacol. 1987 Oct 15;36(20):3487–3494. doi: 10.1016/0006-2952(87)90330-3. [DOI] [PubMed] [Google Scholar]
  31. Varghese A. J., Gulyas S., Mohindra J. K. Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo. Cancer Res. 1976 Oct;36(10):3761–3765. [PubMed] [Google Scholar]
  32. Walling J. M., Deacon J., Holliday S., Stratford I. J. High uptake of RSU 1069 and its analogues melanotic melanomas. Cancer Chemother Pharmacol. 1989;24(1):28–32. doi: 10.1007/BF00254101. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES